Screening with fecal immunochemical tests (FITs) lowers the risk of dying from colorectal cancer (CRC), according to a study published online July 19 in JAMA Network Open. Chyke A. Doubeni, M.D., from ...

Commercially available noninvasive screening tests for colorectal cancer - a fecal immunochemical test (FIT) and the multi-target stool DNAtest (mt-sDNA; or Cologuard ®) - are equally effective for ...

Three-quarters of people prefer to do a fecal immunochemical test (FIT) rather than a colonoscopy for their regular colorectal cancer screening, according to a new Cedars-Sinai study. Unlike ...

Although considered a single class, fecal immunochemical tests (FITs) vary in their ability to detect advanced colorectal neoplasia (ACN) and should not be considered interchangeable, new research ...

Colorectal cancer (CRC) remains the second leading cause of cancer-related deaths in the United States, a troubling fact when considering that CRC is largely preventable and treatable if caught early.

About The Study: This study found that comparable levels of sensitivity and specificity as reported for the multitarget stool RNA (mt-sRNA) test in the colorectal cancer (CRC)-PREVENT study could be ...

About The Study: In this nested case-control study, completing fecal immunochemical test was associated with a lower risk of overall death from colorectal cancer, particularly in the left colon, and ...